West Pharmaceutical Services Announces Third Quarter 20...(ptions or weaknesses in our supply chain...),Health

delivery delays or restrict the availability of raw materials and key

bought-in components and finished products;

-- raw-material price escalation, particularly petroleum-based raw

materials, and our ability to pass raw-material cost increases on to

customers through price increases;

Other Risks:

-- the development, regulatory approval and marketing of new products as a

result of the Company's research and development efforts;

-- the defense of self-developed or in-licensed intellectual property,

including patents, trade and service marks and trade secrets;

-- dependence of normal business operations on information and

communication systems and technologies provided, installed or operated

by third parties;

-- the relative strength of the U.S. dollar in relation to other

currencies, particularly the Euro, British Pound, and Japanese Yen;

-- changes in tax law or loss of beneficial tax incentives;

-- the conclusion of unresolved tax positions consistent with currently

expected outcomes;

and other risks and uncertainties detailed in West's filings with the Securities and Exchange Commission, including our Registration Statement on Form 10-K filed with the SEC on March 1, 2007. You should evaluate any statement in light of these important factors.

Exubera(R) is a registered trademark of Pfizer, Inc.

Contacts:

West Pharmaceutical Services, Inc.

Michael A. Anderson

Vice President and Treasurer

(610) 594-3345

Investors & Financial Media:

Financial Dynamics

Evan Smith/Theresa Kelleher

(212) 850-5600

wst@fd-us.com

Media:

Schwartz Communications

Risa Burgess

(781) 684-0770

westpharma@schwartz-pr.com

WEST PHARMACEUTICAL SERVICES, INC.

'/>"/>